MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell

Jingwen Liu¹
Tingting Meng¹
Ming Yuan¹
Lijuan Wen¹
Bolin Cheng¹
Na Liu¹
Xuan Huang²
Yun Hong³
Hong Yuan¹
Fuqiang Hu¹

¹Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou.
²Department of Pharmacy, School of Medicine Science, Jiaxing University, Jiaxing. ¹The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China

Introduction

Breast cancer is the leading cause of cancer death among females worldwide.¹ Surgery, chemotherapy, radiotherapy, and hormonal therapy are common therapeutic options for breast cancer patients currently; however, there still remains the issue of tumor recurrence, metastasis, and acquisition of drug resistance.²⁻⁴ Emerging evidence suggests that breast cancer stem cells (BCSC), which possess the properties of self-renewal and differentiation, may play critical roles.⁵⁻⁶ Thus, the eradication of BCSC is an important goal to cure breast cancer.⁷ One of the major obstacles toward treatment of BCSC is their resistance to standard chemotherapeutic drugs.⁸⁻⁹ Therefore, increasing the drug sensitivity is a vital step of improved treatment toward BCSC.

Background: One of the major obstacles in the treatment of breast cancer is breast cancer stem cells (BCSC) which are resistant to standard chemotherapeutic drugs. It has been proven that microRNA-200c (miR-200c) can restore sensitivity to microtubule-targeting chemotherapeutic drugs by reducing the expression of class III β-tubulin. In this study, combination therapy with miR-200c and paclitaxel (PTX) mediated by lipid nanoparticles was investigated as an alternative strategy against BCSC.

Materials and methods: A cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane was strategically selected to formulate solid lipid nanoparticles (SLN) for miR-200c delivery. Nanostructured lipid carriers (NLC) with 20 wt% oleic acid were prepared for PTX delivery. Mammospheres, which gained the characteristics of BCSC, were used as a cell model to evaluate the efficiency of combination therapy.

Results: The cationic SLN could condense anionic miRNA to form SLN/miRNA complexes via charge interactions and could protect miRNA from degradation by ribonuclease. SLN/miR-200c complexes achieved 11.6-fold expression of miR-200c after incubation for 24 hours, compared with that of Lipofectamine™ 2000/miR-200c complexes (*P<0.05). Intracellular drug release assay proved that miRNA can be released from SLN/miRNA complexes efficiently in 12 hours after cellular uptake. After BCSC were transfected with SLN/miR-200c, the expression of class III β-tubulin was effectively downregulated and the cellular cytotoxicity of PTX-loaded NLC (NLC/PTX) against BCSC was enhanced significantly (**P<0.01).

Conclusion: The results indicated that the cationic SLN could serve as a promising carrier for miRNA delivery. In addition, the combination therapy of miR-200c and PTX revealed a novel therapeutic strategy for the treatment of BCSC.

Keywords: breast cancer stem cells, microRNA-200c, paclitaxel, solid lipid nanoparticles, nanostructured lipid carriers, combination therapy

This article was published in the following Dove Press journal:
International Journal of Nanomedicine
12 December 2016
Number of times this article has been viewed
MicroRNAs (miRNAs) are a class of small noncoding RNAs of 21–25 nucleotides in length that exert their regulatory effects through posttranscriptional regulation of genes by binding to the 3′-untranslated region of target messenger RNA (mRNA), leading to target mRNA or cleavage translational repression.10 The expression of miRNAs is often altered in cancers, particularly in cancer stem cells, affecting self-renewal and proliferation.11 Thus, miRNA can be used as therapeutic tools to eradicate cancer stem cells.12,13 It has been reported that microRNA-200c (miR-200c) is significantly downregulated in BCSC compared with non-tumorigenic cells.14 Restoration of miRNA-200c can increase chemotherapeutic response of microtubule-binding agents by downregulation of class III β-tubulin (TUBB3).15,16 Based on this, drug combinations using miR-200c and paclitaxel (PTX) may open a new window for therapeutic strategy against BCSC.

Delivery of miRNAs is limited by poor cellular uptake, rapid degradation by nucleases, poor endosomal release, and so on.17,18 Therefore, the development of safe and efficient miRNA carriers is a prerequisite for the success of combination therapy. Currently, the combination of gene and chemical drugs can be classified into three categories: 1) chemotherapy combined with gene carrying nanoparticles;19, 20 codelivery;20 and 3) use of multiple nanocarriers.21 Using separate delivery systems has the advantage of controlling timing and dosage regimen for the chemo and gene drugs.22 Lipid nanoparticles possess many advantages, including biocompatibility, rapid cellular uptake, and potential for large-scale production.23,24 In this respect, we selected a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) to formulate solid lipid nanoparticles (SLN) for miRNA delivery. Nanostructured lipid carriers (NLC) consisting of solid and liquid lipids are a new generation of SLN. NLC have the advantages of improved drug entrapment efficiency (EE) and drug loading (DL) capacity than their SLN counterparts.25 Thus, NLC were applied to deliver PTX.

In this study, the physicochemical properties of SLN and NLC obtained were evaluated separately. The human breast cancer (MCF-7) cells were cultured in nonadherent conditions to form mammospheres. The mammospheres, which are a new generation of SLN (DL) capacity than their SLN counterparts. NLC have the advantages of biocompatibility, rapid cellular uptake, and potential for large-scale production.23,24

Delivery of miRNAs is limited by poor cellular uptake, rapid degradation by nucleases, poor endosomal release, and so on. Therefore, the development of safe and efficient miRNA carriers is a prerequisite for the success of combination therapy. Currently, the combination of gene and chemical drugs can be classified into three categories: 1) chemotherapy combined with gene carrying nanoparticles; codelivery; and 3) use of multiple nanocarriers. Using separate delivery systems has the advantage of controlling timing and dosage regimen for the chemo and gene drugs. Lipid nanoparticles possess many advantages, including biocompatibility, rapid cellular uptake, and potential for large-scale production. In this respect, we selected a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) to formulate solid lipid nanoparticles (SLN) for miRNA delivery. Nanostructured lipid carriers (NLC) consisting of solid and liquid lipids are a new generation of SLN. NLC have the advantages of improved drug entrapment efficiency (EE) and drug loading (DL) capacity than their SLN counterparts. Thus, NLC were applied to deliver PTX.

In this study, the physicochemical properties of SLN and NLC obtained were evaluated separately. The human breast cancer (MCF-7) cells were cultured in nonadherent conditions to form mammospheres. The mammospheres, which were proved to be enriched of BCSC by our previous study (Meng, unpublished data, 2016), were used as an in vitro model to study the combination therapy effect. As TUBB3 is a direct target of miR-200c, real-time polymerase chain reaction (PCR) and Western blot were performed to examine the gene and protein expression of TUBB3 after miR-200c transfection. The cytotoxicity of PTX-loaded NLC after transfection was investigated to verify whether miR-200c delivered by SLN could enhance the therapeutic effects of PTX against BCSC.

Materials and methods

Materials

Monostearin was purchased from Shanghai Chemical Reagent Co. Ltd. (Shanghai, People’s Republic of China). DOTAP was obtained from Lipoid GmbH (Ludwigshafen, Germany). Oleic acid was supplied by Shuanglin Chemical Industry Co. Ltd. (Hangzhou, People’s Republic of China). Octadecanoic acid was purchased from Fluka (Sigma-Aldrich, St Louis, MO, USA). Polyvinyl alcohol (PVA 0486) was obtained from Beijing Chemicals Co. Ltd. (Beijing, People’s Republic of China). Poloxamer 188 was supplied by Shenyang Jiqi Pharmaceutical Co. Ltd. (Shenyang, People’s Republic of China). Tris-base was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Agarose G-10 was obtained from Biowest (Granada, Spain). PTX was purchased from Shanghai Zhongxi Sunve (Shanghai, People’s Republic of China). Taxol was obtained from Bristol-Myers Squibb (New York, NY, USA). Lipopectamine™ was obtained from Thermo Fisher Scientific (Waltham, MA, USA). miR-200c mimics (miR-200c mimics sequence: 5′-UAAUACUGCCGGGUAAUGAUGGA-3′), negative control miRNA, CY3-labeled miRNA (miRNA-CY3), and fluorescein amidite (FAM)-labeled miRNA (miRNA-FAM) were supplied by GenePharma (Shanghai, People’s Republic of China). Fluorescein isothiocyanate (FITC) was purchased from Acros Organic (Fair Lawn, NJ, USA). 4-Nitrophenyl phosphate disodium was purchased from Sigma-Aldrich. Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 1:1 and B27 were purchased from HyClone (Logan, UT, USA). Human recombination epidermal growth factor and human recombination b-fibroblast growth factor were supplied by Perpro Tech Inc. (Rocky Hill, NJ, USA). Insulin was supplied by Sigma-Aldrich Co. B-27 Supplement was obtained from Thermo Fisher Scientific. The bicinchoninic acid (BCA) protein assay kit was purchased from the Beyotime (Shanghai, People’s Republic of China). All other chemicals were analytical reagent grade.

Preparation of SLN and SLN/miRNA complexes

SLN with 0 wt%, 10 wt%, 20 wt%, and 30 wt% content of DOTAP were prepared by aqueous solvent diffusion method reported in our previous study. Briefly, 30 mg monostearin was dissolved in 3 mL ethanol, and then the monostearin was melted at 50°C. Amounts of 3, 6, and 9 mg of DOTAP were used instead of the same amount of monostearin to
prepare SLN with 10 wt%, 20 wt%, and 30 wt% content of DOTAP, respectively. The resulting organic solution was then dispersed rapidly into 30 mL poloxamer 188 solution (0.1%, w/v) agitating (DC-40, Hangzhou Electrical Engineering Instruments, People’s Republic of China) at 400 rpm in 50°C water bath for 5 minutes. Then, the solution was gradually cooled to the room temperature.

For preparation of SLN/miRNA complexes, miRNA solution was added to SLN colloidal solution, and the mixture was incubated for 30 minutes at room temperature.

Preparation of NLC and PTX-loaded NLC
NLC and PTX-loaded NLC (NLC/PTX) were prepared by aqueous solvent diffusion method. An amount of 12 mg monostearin, 12 mg soybean phosphatidylcholine (S100), and 6 mg oleic acid were used as lipid materials and dissolved in 3 mL ethanol at 50°C. The melted solution was dispersed into 30 mL polyvinyl alcohol solution (1%, w/v) agitating at 400 rpm in 50°C water bath for 5 minutes. The pH value of the NLC dispersion was adjusted by addition of 0.1 M acetic acid to form nanoparticle aggregation. NLC were collected by centrifugation (20,000 rpm, 10 minutes). The NLC precipitate was then resuspended in 30 mL polyvinyl alcohol solution (1%, w/v). To prepare NLC/PTX, the same amount of lipid materials with 1.5 mg PTX was mixed, and then followed the method described earlier.

FITC-labeled octadecanoic acid was synthesized according to our previously reported study and was incorporated into the lipid matrix to form fluorescence SLN or NLC.

Characterization of the nanoparticles
The average diameter and zeta potential of nanoparticles were measured by dynamic light scattering using a zetasizer (Nano-ZS90; Malvern Instruments, Malvern, UK).

The morphology of nanoparticles was observed by transmission electron microscopy (JEM-1230EX; JEOL, Tokyo, Japan). Specimens were prepared by dripping suspensions onto copper grids, followed by negative staining with 2% aqueous solution of sodium phosphotungstate.

Gel retardation assay
The capability of cationic SLN to condense miRNA (negative control miRNA) was evaluated on agarose gel electrophoresis (1%, w/v) under a current voltage of 120 V for 25 minutes in a buffer solution (40 mM Tris–HCl, 1%, v/v acetic acid, 1 mM ethylenediaminetetraacetic acid). SLN/miRNA nanoparticles containing 0.13 μg of miRNA were prepared at different weight ratios by varying the concentration of SLN. Images were obtained using an ultraviolet transilluminator and a digital imaging system (GL 200; Kodak, Windsor, CO, USA).

RNase A protection assay
An amount of 2 μL of 10 mg/mL RNase A was added to SLN/miRNA complexes (90:1, w/w, 0.13 μg miRNA/well), and the mixtures were incubated at 37°C for 30 minutes. An amount of 0.5 M ethylenediaminetetraacetic acid was used to terminate the reaction. Subsequently, 10% heparin sodium solution was added to release miRNA from nanoparticles. The final samples were further incubated in an incubator shaker (60 rpm, 37°C), and electrophoresis was performed with 1% agarose gel for 25 minutes at 120 V. The gel was then observed by ultraviolet transilluminator and a digital imaging system.

Drug encapsulation efficiency and DL
The PTX contents were detected by high-performance liquid chromatography (HPLC; Agilent Technologies, Santa Clara, CA, USA). The mobile phase was acetonitrile–water (45:55, v/v) at a rate of 1.0 mL/min at 35°C. The ultraviolet detector was set to 227 nm.

The NLC/PTX was precipitated by adding 0.1 M acetic acid, and then the supernatant was collected after centrifugation. The drug content in the obtained supernatant was measured by HPLC as described earlier. The drug EE and DL of SLN values were calculated by the following equations:

\[
EE = \frac{(W_d - W_s)}{W_d} \times 100\% \quad (1)
\]

\[
DL = \frac{(W_d - W_s)}{(W_d - W_s + W_l)} \times 100\% \quad (2)
\]

where \(W_d\) is the weight of drug added in the system, \(W_s\) is the analyzed weight of drug in supernatant after centrifugation, and \(W_l\) is the weight of lipid added in the system.

In vitro release test
miRNA-FAM was used to form complexes with different weight ratios of SLN to miRNA-FAM. Then, the SLN/miRNA-FAM complexes were suspended in Eppendorf tubes containing Tris-base (pH 7.4). The tubes were placed in an incubator shaker (60 rpm, 37°C). At predetermined time intervals, the suspensions were centrifuged at 20,000 rpm for 10 minutes. The amount of miRNA-FAM released was analyzed by fluorescence spectrophotometer with an
excitation wavelength of 480 nm and an emission wavelength of 520 nm.

To study in vitro release profiles of PTX-loaded NLC, the precipitate of drug-loaded nanoparticles were dispersed in phosphate-buffered saline (PBS) (pH 7.4) containing 1 M sodium salicylate. The sodium salicylate solution can increase the aqueous PTX solubility. Therefore, it was used to provide a good sink condition for PTX. And then the release medium was shaken horizontally (60 rpm, 37°C) using an incubator shaker. At predetermined time intervals, 1 mL of the suspensions was collected and then ultrafiltered/centrifuged. The filters were determined by HPLC as described earlier. The diffusion profile of pure drug dispersion was performed as a comparison.

**BCSC sphere culture**

*Primary cell culture*

MCF-7 cells were cultured in DMEM medium containing fetal bovine serum (10%, v/v), penicillin (100 U/mL), and streptomycin (100 U/mL), and maintained in a humidified 37°C incubator with 5% CO₂.

**Formation of mammospheres**

The serum-free medium (SFM) consisted of human recombinant epidermal growth factor (20 ng/mL), human recombinant basic fibroblast growth factor (20 ng/mL), insulin (5 μg/mL), and B27 supplement (2%, v/v). The single MCF-7 cells were suspended in SFM at a density of 5,000 cells/mL. The medium was added every 5 days. On the fourth, seventh, and ninth day post-cell seeding, images of mammospheres were taken by an inverted microscope.

**Real-time PCR quantification of miR-200c and mRNA**

The mammospheres were treated with miR-200c, SLN/miR-200c, and Lipofectamine™ 2000/miR-200c. Untreated cell spheroids were used as a blank control. After 24 hours, the mammospheres were collected, washed with PBS, and then treated with TRIZol reagent (Thermo Fisher Scientific). Total RNA was extracted by adding chloroform, further purified by isopropanol precipitation. An amount of 500 ng RNA was first reverse transcribed into cDNA with the sequence-specific stem-loop RT primers for miR-200c (ShenGong, Shanghai, People’s Republic of China). Primers for amplification were as follows: 5′-GTCGTATCCAGTGCAGGGTCCGAGG TATTCGACACTGATACGACTCCATC-3′ (stem-loop primer), 5′-GGCCGCGTGAATACGCTTCGGG-3′ (forward primer), and 5′-ATCCAGTCGAGGTTCCGAGG-3′ (reverse primer). The real-time PCR amplification of cDNA was then performed using SYBR Green PCR Master Mix (Takara, Shiga, Japan) on the Step one plus system (Thermo Fisher Scientific). The PCR reaction was conducted at 95°C for 3 minutes, 40 cycles of 95°C for 12 seconds, and 62°C for 40 seconds. The miR-200c expression was then analyzed by the ΔΔCT method and normalized to U6 small nuclear RNA (snRNA) (GenePharma), which was the endogenous control in the corresponding samples.

To measure TUBB3 expression at the mRNA level, 1 μg RNA was transcribed into cDNA. The resulting cDNA was amplified by real time polymerase chain reaction (RT-PCR). Primers for amplification of TUBB3 were as follows: 5′-AGTATCCCGACCAGATCA-3′ (forward primer) and 5′-CATCCGTGTCTTCACCAG-3′ (reverse primer). The PCR reaction was conducted at 95°C for 30 seconds, 40 cycles at 95°C for 5 seconds, and 60°C for 30 seconds. The TUBB3 gene expression was analyzed by the ΔΔCT method, and normalized to GAPDH, which was the endogenous reference in the corresponding samples.

**Intracellular drug release of SLN/miRNA complexes**

To investigate the intracellular drug release of SLN/miRNA complexes, FITC-labeled SLN (FITC-SLN), and miRNA-CY3 were used to prepare fluorescent complexes. Mammospheres were treated with Accutase-Enzyme Cell Detachment Medium to obtain single cell suspension, and then single cells were seeded at a density of 50,000 cells per well in 24-well plate and cultured in growth medium (DMEM, 10% fetal bovine) for 12 hours to attach. FITC-SLN/miRNA-CY3 was added to the culture medium. After incubation for 4 hours, the culture medium was removed, the cells were rinsed twice with PBS, and fresh medium was added. Further incubated for 0, 4, and 12 hours, the cells were washed with PBS and observed by confocal laser scanning microscope (CLSM, IX81-FV1000; Olympus Corporation, Tokyo, Japan).

**Western blot assay**

After transfection for 48 hours, the cell spheres were collected and washed with PBS, then incubated with the radioimmunoprecipitation assay (RIPA) lysis buffer (Shenggong, Shanghai, People’s Republic of China) containing a protease inhibitor on ice for 15 minutes. The cell lysate was centrifuged at 4°C (10,806 rpm, 5 minutes). The supernatant was collected and the total protein concentration was determined using BCA protein assay kit. An amount of 20 μg protein of each sample was separated on 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred to
nitrocellulose membranes, and then blocked with 5% skim milk in PBS containing 0.1% Tween 20 (T-PBS buffer) for 1 hour. After the membrane was washed with T-PBS, the primary antibodies of TUBB3 and β-tubulin diluted in T-PBS were added and incubated for 4 hours at room temperature, respectively. After incubation with appropriate secondary antibody, signals were detected via an enhanced chemiluminescence detection system named enhanced chemiluminescence (ECL) (Shenggong).

### Cellular uptake of fluorescent NLC

Mammospheres were treated with FITC-labeled NLC for 12 and 24 hours. Then, the cells were washed twice with PBS (pH 7.4) and observed by CLSM with a 40× water immersion objective. Excitation wavelength and emission wavelength were 488 and 520 nm, respectively. Stacked images were obtained by piling up the images scanned layer by layer. Each scanning layer was 1.2 μm in thickness.

### In vitro cytotoxicity

The in vitro anticancer activity of combined gene-chemotherapy was evaluated by a cell viability assay. Mammospheres grown in 96-well plates were incubated with naked miR-200c, SLN/miRNA negative control (SLN/miRNA NC), SLN/miR-200c, and Lipofectamine™ 2000/miR-200c (equal miRNA concentration) for 24 hours. Untreated cell spheroids were used as a blank control. Afterward, all groups were treated with taxol or PTX-loaded NLC with different concentration. Cells were further incubated for 48 hours. The percentage of the viable cells was measured by an acid phosphatase assay. The plates were centrifuged (10 minutes, 400×g) to spin down the spheroids. The supernatant was discarded and the cells were washed with PBS. Centrifugation was repeated, and PBS was added to the supernatant to reach a final volume of 100 μL. Then, 100 μL of the assay buffer (0.1 M sodium acetate, 0.1% Triton-X-100, 2 mg/mL of para-nitrophenylphosphate) was added per well and incubated for 90 minutes at 37°C. Ten microliters of 1 mol/L NaOH solution was added to each well to terminate the reaction. The absorbances of each well was measured at 405 nm using a microplate reader (SpectraMax M5; Molecular Devices LLC, Sunnyvale, CA, USA).

### Statistical analysis

The results were expressed as mean ± standard deviation. Statistical significance was analyzed using t-test. The resultant P-value was expressed as *P<0.05 and **P<0.01. Differences were considered to be statistically significant if P-value was <0.05.

### Results and discussion

#### Characterization of SLN and NLC

SLN, NLC, and PTX-loaded NLC (NLC/PTX) were prepared by solvent diffusion method as reported in our previous work. SLN/miRNA nanoparticles were prepared by mixing an appropriate amount of SLN and miRNAs at room temperature.

Number average diameters and zeta potential of SLN containing different amount of DOTAP are summarized in Table 2. When the weight ratio of SLN to miRNA was 60:1, the average size increased to 141.8±3.9 nm and the zeta potential was −1.6±0.9 mV. The larger size was probably because the nanoparticles with this weight ratio were in an unstable state and easily aggregated.

The mean particle sizes of NLC and NLC/PTX were 56.1±9.0 and 64.5±3.3 nm, respectively. The zeta potential of NLC and NLC/PTX was −17.1±0.2 and −16.4±0.3, respectively. EE and DL of NLC/PTX were 73.33±2.03% and 3.51±0.07%, respectively.

#### Table 1 The average dₙ, ζ, and PI of SLN containing different amount of DOTAP

| DOTAP ratio (wt%) | dₙ (nm) | Z (mV) | PI   |
|-------------------|---------|--------|------|
| 0                 | 65.9±13.2 | −19.7±0.7 | 0.18±0.01 |
| 10                | 48.0±10.5 | 3.9±1.0  | 0.30±0.02 |
| 20                | 28.4±4.2  | 18.4±1.3 | 0.24±0.01 |
| 30                | 31.2±2.6  | 18.7±1.0 | 0.34±0.06 |

Note: Data presented as mean ± standard deviation. **Abbreviations: DOTAP, 1,2-dioleyl-3-trimethylammonium-propane; dₙ, diameter; PI, polydispersity index; SLN, solid lipid nanoparticles; ζ, zeta potential.**

#### Table 2 The average dₙ, ζ, and PI of SLN/miRNA complexes containing different amount of SLN to miRNA

| SLN/miRNA (w/w) | dₙ (nm) | ζ (mV) | PI   |
|-----------------|---------|--------|------|
| 60:1            | 141.8±3.9 | −1.6±0.9 | 0.51±0.17 |
| 90:1            | 36.1±3.0  | 14.7±0.9 | 0.49±0.14 |
| 120:1           | 48.4±4.0  | 15.5±0.3 | 0.41±0.03 |

Note: Data presented as mean ± standard deviation. **Abbreviations: dₙ, diameter; PI, polydispersity index; SLN, solid lipid nanoparticles; ζ, zeta potential.**
Transmission electron microscopy was used to investigate the morphology of SLN, SLN/miRNA, NLC, and NLC/PTX. The sizes of nanoparticles, which are shown in transmission electron microscopy pictures (Figure 1), were consistent with the results measured by Zetasizer. The pictures exhibited that all the nanoparticles had spherical-like shapes with smooth surfaces.

**Gel retardation assay**

The ability of the cationic SLN to bind miRNA was investigated by agarose gel electrophoresis. Gradual miRNA retardation was observed when the weight ratio of SLN to miRNA in the complexes increased. When the weight ratio was above 30, SLN/miRNA nanoparticles were retarded completely (Figure 2A).

**RNase A protection assay**

The miRNAs are labile in serum; accordingly, it is important to protect them from degradation and maintain their stability. In this study, RNase A was used to evaluate the stability of miRNA in SLN/miRNAs complexes. The result is shown in Figure 2B. Compared with the lane of free miRNA treated without RNase A, no band was observed from the lane of free miRNA treated with RNase A. In contrast, clear bands could be found from the lanes of SLN/miRNA, which demonstrated that SLN could effectively protect miRNA from degradation by ribonuclease.

**In vitro release test**

The in vitro release study of miRNA from SLN/miRNA was carried out in Tris-base (pH 7.4). The calibration curve for the quantification of miRNA-FAM was linear over the range of standard concentration of miRNA-FAM at 1–300 nmol/L with a correlation coefficient of $R^2=0.9996$. Release profiles of SLN/miRNA complexes with different weight ratios are illustrated in Figure 3A. When the complexes were prepared at a weight ratio of 60, a cumulative release of 48.24% was observed in 4 hours and 95.64% in 12 hours. At a weight ratio of 90, the miRNA was released at 32.71% in 4 hours and 87.30% in 12 hours. A higher weight ratio of SLN to miRNA led to a slower release of miRNA from the complexes. At a weight ratio of 120, miRNA was released at a much slower rate, with the release of 16.25% for 4 hours and 45.05% for 12 hours. The results suggested that the release rate of miRNA could be adjusted by varying the charge ratio of SLN to miRNA.

The release rate of PTX from NLC/PTX was measured by HPLC (Figure 3B). The calibration curve for the quantification of PTX was linear over the range of standard concentration of PTX at 0.1–100 μg/mL with a correlation coefficient of $R^2=0.9998$. The limitation of detection was 0.01 μg/mL. A burst drug release was found at the initial 8 hours. After that, the drug was released relatively slowly. This result was consistent with our previous study. The distribution of liquid lipid in nanoparticles matrix probably contributed.
Figure 2 Gel retardation analyses (A) of SLN/miRNA complexes prepared at different weight ratios and RNase A protection assay (B) of SLN/miRNA complexes.

Notes: In (B), lanes 1–4 represent naked miRNA, naked miRNA + RNase, SLN/miRNA, and SLN/miRNA + RNase, respectively. SLN/miRNA complexes were prepared at the weight ratio of 90.

Abbreviation: SLN, solid lipid nanoparticles.

to the drug release profiles. Drugs were mostly incorporated into the liquid lipid, which was mostly located at the shell of nanoparticles instead of the core. As a result, the drugs could be released easily through the drug diffusion and the matrix erosion manners in initial hours and exhibited a sustained release afterward.

Formulation of mammosphere

Mammosphere-forming culture condition has been proven to be an efficient way to enrich tumor stem cells. Our previous work confirmed that MCF-7 cells under this condition of cultivation had gained the characteristics as BCSC. The percentage of CD44+/CD24− expression, which is a cancer stem cell marker, increased to 36.51%.

The morphology of mammospheres was observed on an inverted microscope during spheroid growth. As shown in Figure 4, breast cancer cells (MCF-7) grown in SFM resulted in the formation of cellular spheroids. Mammospheres were packed tightly and were ~100 μm in diameter by 7 days of incubation. After 9 days under SFM culture conditions, the mammospheres exhibited a compact, rounded shape and attained a diameter of 100–200 μm. The seventh day was considered as a treatment initiation point for further study.

Cellular uptake of SLN/miRNA complexes

To investigate the cellular uptake of SLN/miR-200c complexes, the miR-200c expression after transfection...
was evaluated. From Figure 5, naked miR-200c only had 1.95-fold expression of miR-200c over blank group, which demonstrated that miR-200c cannot be delivered efficiently without suitable gene carriers. Compared with the commercial transfection agent Lipofectamine™ 2000, SLN achieved an 11.6-fold expression of miR-200c. This result suggested that SLN had a relatively higher cellular uptake efficiency against mammospheres, indicating its great potential for efficient miRNA delivery.

Intracellular release of SLN/miR-200c complexes

As only free miRNA could interact with target mRNA in cytoplasm and exert its pharmacological action, the intracellular drug release behaviors of the SLN/miRNA complexes against single-layer BCSC were investigated. FITC-SLN and miRNA-CY3 were used to prepare fluorescent SLN/miRNA complexes. The images were obtained from CLSM and the results of colocalization of SLN with miRNA were calculated by MetaMorph software.

After cells were incubated with FITC-SLN/miRNA-CY3 for 4 hours, the culture medium was removed and replaced with fresh medium. Figure 6A shows the colocalization of SLN with miRNA in cells after further incubation for different time periods. The overlap of red fluorescence and green fluorescence was decreased gradually with time. Figure 6B shows that from 0 to 12 hours, the area a (FITC-SLN) overlap b (miRNA-CY3) decreased from 92% to 13% and the area b overlap a decreased from 85% to 21%, indicating that SLN/miRNA complexes can effectively release miRNA over time.

The TUBB3 mRNA and protein expression

TUBB3 is a direct target of miR-200c.15 We used real-time PCR to investigate the effect of SLN/miR-200c complexes on TUBB3 mRNA expression in mammospheres. Compared with blank control group, SLN/miR-200c and Lipofectamine™ 2000/miR-200c complexes almost did not influence TUBB3 expression in mRNA level (Figure 7A). As the miRNA can direct the cleavage of target mRNAs or negatively regulate target expression at the transcription level,30 we performed Western blot to examine the protein expression of TUBB3. As it shown in Figure 7B, SLN/miR-200c significantly decreased TUBB3 protein expression, and the same effect was found in the Lipofectamine™ 2000/miR-200c-treated group.

The decrease of TUBB3 mRNA was not observed after transfection with SLN/miR-200c. However, an obvious decrease in TUBB3 protein level was found, which indicated that miR-200c may affect the expression of TUBB3 primarily through inhibition of TUBB3 translation.
Cellular uptake of NLC

The cellular uptakes of fluorescent NLC were viewed by CLSM. Figure 8 shows single section images (A and C) of different depth and 3D images (B and D) reconstructed by piling up the layers of different depths of mammospheres after incubation with fluorescent NLC for 12 and 24 hours, respectively. As shown in Figure 8B and D, obvious fluorescence was observed after 12 hours and the fluorescence intensity was enhanced in 24 hours. The images showed that more FITC-labeled NLC were internalized by mammospheres with incubation for a longer time. At the same depth (Figure 8A and C), the mammosphere presented more fluorescent NLC in the inner cell layers after 24-hour incubation. It illustrated that the NLC went deeper into the mammospheres over time. The results indicated that the cellular uptakes of NLC were time-dependent.

Figure 6 Intracellular miRNA release profiles of SLN/miRNA complexes. 
Notes: The mammospheres were treated with enzyme to obtain single-layer cells and then incubated with FITC-SLN/miRNA-CY3 for 4 hours. Then, the incubation medium was removed and replaced, and the cells were observed for the next 0, 4, and 12 hours. (A) and (B) represent colocalization micrographs and analysis of SLN with miRNA, respectively. The green color represents SLN, and the red color represents miRNA. Area a (FITC-labeled SLN) overlap b (CY-3-labeled miRNA) represents the proportion of SLN that was occupied by miRNA, and area b overlap a shows the proportion of miRNA that was occupied by SLN. Scale bar: 20 μm.
Abbreviations: FITC, fluorescein isothiocyanate; SLN, solid lipid nanoparticles.

Figure 7 TUBB3 mRNA expression (A) and protein expression (B) after transfection.
Abbreviations: SLN, solid lipid nanoparticles; TUBB3, class III beta-tubulin.
Figure 8  Single section images (A) and stacked images (B) of mammospheres after incubation with FITC-labeled NLC for 12 hours. Single section images (C) and stacked images (D) of mammospheres after incubation with FITC-labeled NLC for 24 hours. Scale bar: 100 μm.

Abbreviations: FITC, fluorescein isothiocyanate; NLC, nanostructured lipid nanoparticles.
In the meanwhile, confocal microscopy revealed that NLC were localized in cytosol. As the action target of PTX is microtubules in the cytoplasm, the result showed that NLC could deliver PTX into cells and enable localization of PTX to its intracellular site of action.

**In vitro anticancer efficacy**

The cytotoxicity is strongly dependent on the cationic lipid used in the matrix lipid. Here, we strategically selected DOTAP to formulate SLN because it is relatively well tolerated compared with other cationic lipids. The cytotoxicity was evaluated by acid phosphatase assay and the morphology changes of mammospheres after transfection were observed by an inverted microscope. The cell viabilities of SLN/miRNA NC and Lipofectamine™ 2000/miRNA NC complexes were 96.42% and 80.8%, respectively (***P<0.01) (Figure 9A). As shown in Figure 9B, the influence of SLN/miRNA NC on mammospheres was almost negligible, while the mammospheres treated by Lipofectamine™ 2000/miR-200c became less compact and regular. The results indicated that SLN were safer gene carriers for miRNA delivery than Lipofectamine™ 2000.

NLC exhibited low cytotoxicity at the concentration of 10–100 μg/mL (Figure 9C). Even when a high concentration

![Figure 9](image_url)

**Figure 9** (A) Cell viabilities of SLN, SLN/miRNA NC, Lipofectamine™ 2000, and Lipofectamine™ 2000/miRNA NC; (B) Light microscope images of mammospheres under different treatments, scale bar: 100 μm; and (C) Cell viabilities of NLC at various concentrations. ***P<0.05, **P<0.01.

**Abbreviations:** NLC, nanostructured lipid nanoparticles; SLN, solid lipid nanoparticles; SLN/miRNA NC, SLN/miRNA negative control.
was used (400 μg/mL), ~50% cells in mammospheres survived, suggesting that NLC could be applied as a safe carrier for chemotherapeutical drug delivery.

It has been reported that restoration of miR-200c could increase the sensitivity to microtubule-targeting chemotherapeutic drugs by reduction of the expression of TUBB3. To verify whether miR-200c delivered by SLN could enhance the effects of PTX against BCSC, the in vitro anticancer efficacies of NLC/PTX under different transfection conditions were compared. The in vitro anticancer efficacy was defined in terms of the 50% growth inhibition (half maximal inhibitory concentration [IC50] value) based on an acid phosphatase assay.

From Table 3, the IC50 value for taxol after mammospheres transfected with SLN/miR-200c (1.08±0.13 μg/mL) was significantly lower than that of blank control group (5.16±0.23 μg/mL), and IC50 value for NLC/PTX after treated with SLN/miR-200c (0.28±0.06 μg/mL) was also significantly lower than that of the blank control group (2.06±0.13 μg/mL) (***P<0.01). These results revealed that miR-200c could act as a sensitizer of PTX when it was delivered by SLN. The IC50 value for taxol after mammospheres incubated with naked miR-200c showed no difference compared with blank control, and no difference was seen between the IC50 values for NLC/PTX of blank group and miR-200c treated group, suggesting that miR-200c could not exert their pharmacological effect without gene carriers.

Under the same transfection conditions, the IC50 values of PTX-loaded NLC were lower than that of taxol. This means the drug internalization into cell could be enhanced by the encapsulation of NLC matrix. The improved cytotoxicity was probably caused from two reasons. One reason is that the internalization of drug into cells was enhanced when the drug was incorporated in NLC, due to the membrane affinity of lipid material and nano-scaled size of NLC. The other one is that NLC accumulated in cytoplasm can serve as a drug container releasing the drug continuously.

**Conclusion**

In summary, this study reports the development of lipid nanoparticles for separate delivery of miR-200c and PTX. It has been shown that the SLN/miRNA complexes possessed the ability to protect miRNA from degradation and release miRNA effectively after cellular uptake. Consequently, this formulation could sensitize the cytotoxicity of NLC/PTX against BCSC by negatively regulating TUBB3 expression. In addition, the SLN showed a significant less cytotoxicity compared to Lipofectamine™ 2000. These results suggest that the cationic SLN could serve as a promising carrier for miRNA delivery. In addition, the combination therapy of miR-200c and PTX revealed a novel therapeutic strategy for the treatment of BCSC.

**Acknowledgments**

The authors thank the National Natural Science Foundation of China (NSFC No 81273442 81473144) and the Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents for their financial support.

**Disclosure**

The authors report no conflicts of interest in this work.

Table 3 IC50 values of taxol and NLC/PTX against mammospheres after transfection.

| Transfection conditions | IC50 (μg/mL) |
|-------------------------|-------------|
|                         | Taxol       | NLC/PTX     |
| Without transfection    | 5.16±0.23   | 2.06±0.13   |
| SLN/miRNA NC            | 4.85±0.24   | 1.86±0.16   |
| miR-200c                | 4.80±0.28   | 1.90±0.16   |
| Lipofectamine™/miR-200c | 1.24±0.15** | 0.29±0.05** |
| SLN/miR-200c            | 1.08±0.13** | 0.28±0.06** |

**Notes:** ***P<0.01 compared with blank control group. Data presented as mean ± standard deviation.

**Abbreviations:** IC50, half maximal inhibitory concentration; NLC, nanostructured lipid nanoparticles; PTX, paclitaxel; SLN, solid lipid nanoparticles; SLN/miRNA NC, SLN/miRNA negative control.

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. *CA Cancer J Clin*. 2015;65(2):87–108.
2. Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. *Acta Oncol*. 2011;50(2):187–193.
3. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. *N Engl J Med*. 2011;365(5):412–421.
4. Shibata D. Molecular tumor clocks to study the evolution of drug resistance. *Mol Pharm*. 2011;8(6):2050–2054.
5. Al-Haji M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A*. 2003;100(7):3983–3988.
6. Velasco-Velázquez MA, Homs I, De La Fuente M, Pestell RG. Breast cancer stem cells. *Int J Biochem Cell Biol*. 2012;44(4):573–577.
7. Kim YJ, Liu Y, Li S, et al. Co-ereadation of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment. *Mol Pharm*. 2015;12(8):2811–2822.
8. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer*. 2005;5(4):275–284.
9. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. *Mol Cell*. 2014;54(5):716–727.
10. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136(2):215–233.
11. Iorio MV, Croce CM. MicroRNA involvement in human cancer. *Carcinogenesis*. 2012;33(6):1126–1133.
12. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. *Cancer Res.* 2011;71(18):5950–5954.
13. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. *Curr Protoc Pharmacol.* 2013;Chapter 14:Unit 14.25.
14. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. *Cell.* 2009;138(3):592–603.
15. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. *Mol Cancer Ther.* 2009;8(5):1055–1066.
16. Cochrane DR, Howe EN, Spoelstra NS, et al. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. *J Oncol.* 2010;2010:821717.
17. Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. *Adv Drug Deliv Rev.* 2015;81:142–160.
18. Bravo V, Rosero S, Ricordi C, et al. Instability of miRNA and cDNAs derivatives in RNA preparations. *Biochem Biophys Res Commun.* 2007;353(4):1052–1055.
19. Bai M, Shen M, Teng Y, et al. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with Ultrasound. *Oncotarget.* 2015;6(41):43779–43790.
20. Yao Y, Su Z, Liang Y, Zhang N. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. *Int J Nanomedicine.* 2015;10:6185–6197.
21. Yoon GY, Son S, Lee SJ, et al. Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA. *Sci Rep.* 2014;4:8678.
22. Young Yhee J, Son S, Lee H, et al. Nanoparticle-based combination therapy for cancer treatment. *Curr Pharm Des.* 2015;21(22):3158–3166.
23. Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. *J Pharm Invest.* 2013;43(5):353–362.
24. He SN, Li YL, Yan JJ, et al. Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery. *Int J Nanomedicine.* 2013;8:2859–2869.
25. Hu FQ, Zhang Y, Du YZ, Yuan H. Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. *Int J Pharm.* 2008;348(1):146–152.
26. Morrill M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. *Biomaterials.* 2008;29(24):3477–3496.
27. Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. *Expert Opin Drug Deliv.* 2013;10(9):1259–1273.
28. Hu FQ, Jiang SP, Du YZ, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. *Colloids and Surf. B: Bio interfaces.* 2005;45(3):167–173.
29. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes Dev.* 2003;17(10):1253–1270.
30. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. *Biochim Biophys Acta.* 2010;1803(11):1231–1243.
31. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. *Eur J Pharm Biopharm.* 2003;57(2):155–162.
32. Friedrich J, Eder W, Castaneda J, et al. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. *J Biomol Screen.* 2007;12(7):925–937.